Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Airway

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44351   clinical trials with a EudraCT protocol, of which   7378   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,312 result(s) found for: Airway. Displaying page 8 of 66.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    EudraCT Number: 2015-003879-29 Sponsor Protocol Number: 1237.49 Start Date*: 2015-12-30
    Sponsor Name:Boehringer Ingelheim Finland Ky
    Full Title: A 4-week, randomised, double-blind, parallel group study to evaluate the efficacy and safety of tiotropium + olodaterol fixed dose combination (5/5 µg) delivered by the Respimat® inhaler versus the...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) AT (Completed) SI (Completed) DK (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-000301-11 Sponsor Protocol Number: CQAB149B2346 Start Date*: 2008-03-14
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 12-week treatment, multi-center, randomized, double-blind, placebo controlled, parallel group study to assess the efficacy and safety of indacaterol (150 µg o.d.) in patients with chronic obstruc...
    Medical condition: COPD: chronic obstructive pulmonary disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DK (Prematurely Ended) LT (Prematurely Ended) FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-005205-40 Sponsor Protocol Number: RPL554-CO-203 Start Date*: 2017-08-29
    Sponsor Name:Verona Pharma plc
    Full Title: A Phase IIb, randomized, double blind, placebo controlled, dose ranging study to assess the effect of RPL554 in patients with moderate to severe COPD.
    Medical condition: moderate to severe Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) BG (Completed) GB (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2021-000692-36 Sponsor Protocol Number: CCSJ117B12201 Start Date*: 2021-12-15
    Sponsor Name:Novartis Pharma AG
    Full Title: A 12-week, randomized, participant-and investigator-blinded, placebo-controlled, parallel group study to explore the efficacy, pharmacodynamics, safety, and pharmacokinetics of two doses of inhaled...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Prematurely Ended) DE (Completed) BE (Prematurely Ended) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2009-010668-40 Sponsor Protocol Number: 1237.5 Start Date*: 2011-07-29
    Sponsor Name:Boehringer Ingelheim bv [...]
    1. Boehringer Ingelheim bv
    2. Boehringer Ingelheim bv
    Full Title: A randomised, double-blind, parallel group study to assess the efficacy and safety of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination (2.5 μg / 5 μ...
    Medical condition: Patients with Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FI (Completed) PT (Completed) SI (Completed) CZ (Completed) DE (Completed) HU (Completed) DK (Completed) EE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-005101-39 Sponsor Protocol Number: M/34273/30 Start Date*: 2008-08-19
    Sponsor Name:Laboratorios Almirall, S.A.
    Full Title: A 52-WEEK RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLLED, MULTICENTRE CLINICAL TRIAL, TO ASSESS THE EFFICACY AND SAFETY OF 200 μg OF THE ANTICHOLINERGIC LAS 34273 COMPARED TO PLACEBO,...
    Medical condition: Maintenance treatment of patients with moderate to severe stable chronic obstructive pulmonary disorder.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10009033 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) CZ (Completed) BE (Completed) GB (Completed) AT (Completed) ES (Completed) DK (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022895-30 Sponsor Protocol Number: CCD-1007-PR-0045 Start Date*: 2011-08-25
    Sponsor Name:Chiesi Farmaceutici S.p.A.
    Full Title: A 12-week, multicentre, randomised, double-blind, double-dummy, 2-arm parallel group study comparing the efficacy and safety of Foster® 100/6 (beclomethasone dipropionate 100 µg plus formoterol 6 µ...
    Medical condition: Male or female patients aged more or equal than 40 years with Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-004647-74 Sponsor Protocol Number: LPS15834 Start Date*: 2020-10-27
    Sponsor Name:Sanofi-Aventis Groupe
    Full Title: Randomized, double blind, placebo controlled study to evaluate the effect of dupilumab on airway inflammation through assessments of lung function, mucus plugging and other lung imaging parameters ...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed) SE (Ongoing) PT (Completed) ES (Ongoing) BG (Completed) FR (Completed) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2013-002243-29 Sponsor Protocol Number: 1237.25 Start Date*: 2013-10-18
    Sponsor Name:Boehringer Ingelheim Ky
    Full Title: A randomised, double-blind, placebo- and active-controlled parallel group study to assess the efficacy of 12 weeks of once daily treatment of two doses of orally inhaled tiotropium + olodaterol fix...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) GB (Completed) CZ (Completed) ES (Completed) DK (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-001934-28 Sponsor Protocol Number: 1222.14 Start Date*: 2008-11-18
    Sponsor Name:Boehringer Ingelheim Finland Ky
    Full Title: A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 μg [2 actuat...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SE (Completed) CZ (Completed) DK (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-001654-65 Sponsor Protocol Number: PDY16967 Start Date*: 2021-11-30
    Sponsor Name:Sanofi-Aventis Recherche & Developpement
    Full Title: A Phase 2a, open label, two-part study to evaluate the mechanism of action of itepekimab (anti-IL-33 mAb) on airway inflammation in patients with chronic obstructive pulmonary disease (COPD)
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    26.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned) DK (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-001122-42 Sponsor Protocol Number: WB29804 Start Date*: 2015-10-12
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Phase II, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of lebrikizumab in patients with chronic obstructive pulmonary disease and a history of exacerbations
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2009-014594-40 Sponsor Protocol Number: D0520C00014 Start Date*: 2010-02-04
    Sponsor Name:AstraZeneca AB
    Full Title: A 12-week, Phase-II, Double-Blind, Placebo-Controlled, Randomised, Parallel-Group, Multi-Centre Study to Assess the Effect of 60 mg AZD9668 Administered Orally Twice Daily on Structural Changes in ...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    12.0 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2004-005238-37 Sponsor Protocol Number: 1184.10 Start Date*: 2005-07-06
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A single dose, placebo-controlled, randomized, double-blind, double-dummy, crossover efficacy, pharmacokinetics and safety comparison of salmeterol inhalation powder (25 µg salmeterol), administere...
    Medical condition: All patients must have a diagnosis of chronic obstructive pulmonary disease and must meet the following spirometric criteria: Patients must have relatively stable airway obstruction with a pre-dose...
    Disease: Version SOC Term Classification Code Term Level
    8.0 10010952 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-003077-42 Sponsor Protocol Number: CE01-204 Start Date*: 2015-02-06
    Sponsor Name:Imperial College, London
    Full Title: A single-centre, double-blind, randomised, placebo-controlled crossover study to evaluate the effect of solithromycin on airway inflammation in male and female patients with chronic obstructive pul...
    Medical condition: Chronic Obstructive Pulmonary Disease.
    Disease: Version SOC Term Classification Code Term Level
    18.0 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-000918-13 Sponsor Protocol Number: 1184.12 Start Date*: 2005-07-06
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A single dose, placebo-controlled, randomized, double-blind, double-dummy, crossover efficacy, pharmacokinetics and safety comparison of salmeterol inhalation powder (12.5 µg, 25 µg and 50 µg salme...
    Medical condition: All patients must have a diagnosis of chronic obstructive pulmonary disease and must meet the following spirometric criteria: Patients must have relatively stable airway obstruction with a pre-dose...
    Disease: Version SOC Term Classification Code Term Level
    8.0 10010952 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-004031-31 Sponsor Protocol Number: RVH006 Start Date*: 2011-11-15
    Sponsor Name:RespiVert Ltd
    Full Title: A randomised, double-blind, placebo-controlled, parallel group study to evaluate the safety and tolerability of treatment with repeat doses of inhaled RV568 in patients with COPD.
    Medical condition: chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-001940-71 Sponsor Protocol Number: BV2013/5 Start Date*: 2013-12-10
    Sponsor Name:OM Pharma SA
    Full Title: A Randomized, Placebo Controlled, Double Blinded, Mechanistic trial to investigate the effects of Broncho-Vaxom (OM-85 BV) on the innate immune system in patients with COPD
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-004473-41 Sponsor Protocol Number: 2016RC22 Start Date*: 2017-03-21
    Sponsor Name:University of Dundee and NHS Tayside
    Full Title: INvestigating COPD Outcomes, Genomics and Neutrophilic Inflammation with Tiotropium and Olodaterol (INCOGNITO trial)
    Medical condition: Chronic obstructive pulmonary disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000015472 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-002376-34 Sponsor Protocol Number: CQAB149B2336 Start Date*: 2007-07-20
    Sponsor Name:NOVARTIS FARMA
    Full Title: A 26-week treatment, multi center, randomized, double blind, double dummy, placebo controlled, parallel group study to assess the efficacy and safety of indacaterol (150 μg o.d.) in patients w...
    Medical condition: COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009026 Chronic obstructive airways disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed) FI (Completed) HU (Completed) CZ (Completed) DK (Completed) IS (Completed) SK (Completed) FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jul 20 08:19:04 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA